A型肉毒毒素注射治疗增生性痤疮瘢痕的远期疗效
研究纳入26例痤疮瘢痕患者,接受不超过100单位的A型肉毒毒素注射,采用ECCA评分在治疗前及复诊时评估,平均随访39.23个月。结果显示ECCA评分在治疗后各时间点较治疗前显著下降,平均无复发期为28.354±1.775个月,无复发期与治疗前ECCA评分、注射次数、BTXA剂量及病程相关。结论认为BTXA注射可短期和长期减轻炎症、改善瘢痕质地。
要点
- BTXA注射可显著降低增生性痤疮瘢痕的ECCA评分,短期与长期均有效。
- 平均无复发期为28.354±1.775个月,治疗前ECCA评分和注射次数与无复发期相关。
- BTXA剂量和病程对无复发期有统计学意义,年龄和性别无统计学意义。
核心结论
- BTXA注射可在短期和长期随访中减轻增生性痤疮瘢痕患者的炎症并改善瘢痕质地。
研究设计与样本
- 对26例痤疮瘢痕患者进行BTXA注射,剂量在100单位以内,平均随访39.23个月。
- 采用ECCA评分在治疗前和复诊时评估,使用SPSS 21.0进行ANOVA、Kaplan-Meier生存曲线和Pearson检验。
主要发现
- 平均ECCA评分治疗前为103.460±36.872,治疗后6个月为79.620±37.146,12个月为63.160±24.049,18个月为47.500±4.629,24个月为50.000±0.000,任意两组间差异均有统计学意义(P<0.01)。
- 平均无复发期为28.354±1.775个月。
- 无复发期与治疗前ECCA评分和注射次数相关(P<0.01),BTXA剂量和病程也有统计学意义(P<0.05),年龄和性别无统计学意义(P>0.05)。
临床怎么用
- 对于增生性痤疮瘢痕患者,可考虑BTXA注射作为改善炎症和瘢痕质地的治疗选择。
- 治疗前ECCA评分较高和注射次数可能影响无复发期,临床可据此评估复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate both the short-and long-term effect of botulinum toxin type A (BTXA) injection on hypertrophic ache scar. METHODS: A total of 26 patients with acne scar received BTXA injection of within 100 units. The effect was evaluated using the ECCA grading scale before treatment and during clinic re-visit, which based on history of acne scar and number of scar area.The short-and long-term effect was recorded. The average follow-up period was 39.23 months. All results were evaluated by SPSS 21.0.ANOVA was used to evaluate average value and standard deviation of ECCA grading scale. Kaplan-Meier survival curve was used to evaluate relapse-free period, and Pearson test was used to detect relevant factors of relapse-free period. UNLABELLED: Results The BTXA injection showed significant positive long-term effect on inflammatory or hypertrophic acne scar. The average ECCA grading scale was 103.460 ±36.872 before treatment,79.620 ±37.146 at 6 months after treatment,63.160 ±24.049 at 12 months after treatment,47.500 ±4.629 at 18 months after treatment, and 50.000 ± 0.000 at 24 months after treatment,showing significant differences between any of two groups (P < 0.01).Average relapse free period was 28.354 ± 1.775 months. Relapse-free period was related to ECCA grading scale pre treatment and injection times (P < 0.01); meanwhile, dose of BTXA and length of disease all had statistical significance (P < 0.05); however, age and gender had no statistical significance (P > 0.05). CONCLUSIONS: The BTXA injection can relieve inflammation and improve scar texture in patients with hypertrophic acne scar in both the short-and long-term follow-up.
引用
- [Long-term effect of botulinum toxin type A injection on hypertrophic acne scar]. Zhonghua Zheng Xing Wai Ke Za Zhi. 2016. PMID: 30067322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。